Actively Recruiting

Age: 18Years - 75Years
All Genders
NCT03356236

Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation

Led by Yue Han · Updated on 2024-05-31

828

Participants Needed

17

Research Sites

350 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To evaluate the efficacy and safety of Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma following Local Ablation

CONDITIONS

Official Title

Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 75 years, male or female
  • Diagnosed with hepatocarcinoma based on tissue examination or imaging criteria
  • Radiographic confirmation of cancer elimination four weeks after local ablation with complete response
  • Solitary tumor smaller than 5 cm, or up to 3 tumors with largest under 3 cm
  • Hemoglobin ≥90 g/L, platelets ≥60×10⁹/L, absolute neutrophil count >1.0×10⁹/L, prothrombin activity >50%, serum creatinine less than 1.5 times upper limit of normal, total bilirubin <51.3 µmol/L
  • ECOG performance status score of 0 to 1
  • Liver function classified as Child-Pugh grade A or B
  • History of TACE treatment for hepatocarcinoma no more than twice
  • Volunteered to participate, signed informed consent, and agree to cooperate with data collection
Not Eligible

You will not qualify if you...

  • Cancer cells not eliminated after four weeks of local ablation as shown by radiographic testing
  • Presence of embolism in large liver blood vessels, extrahepatic metastasis, or liver transplantation
  • Receiving or planned chemotherapy or molecular targeted therapy
  • Planned to receive TACE treatment for hepatocarcinoma
  • No prior treatment with Huaier granules
  • History of diabetes
  • Uncontrolled or likely to develop ascites, hepatic encephalopathy, or upper gastrointestinal bleeding
  • Severe cardiopulmonary insufficiency, renal insufficiency, or severe mental illness
  • Other infectious diseases excluding viral hepatitis
  • Unable to take oral medication
  • Any condition deemed unsuitable for study participation by investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 17 locations

1

The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Actively Recruiting

2

Shijiazhuang Fifth Hospital

Shijiazhuang, Hebei, China

Actively Recruiting

3

Affiliated Cancer Hospital of Harbin Medical University

Harbin, Heilongjiang, China

Actively Recruiting

4

Henan Cancer Hospital

Zhengzhou, Henan, China

Actively Recruiting

5

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

Wuhan, Hubei, China

Actively Recruiting

6

The Affiliated Zhongshan Hospital of Dalian University

Dalian, Liaoning, China

Actively Recruiting

7

The Second Hospital of Dalian Medical University

Dalian, Liaoning, China

Actively Recruiting

8

Shandong Provincial Hospital

Jinan, Shandong, China

Actively Recruiting

9

The Second Hospital of Shandong University

Jinan, Shandong, China

Actively Recruiting

10

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

Actively Recruiting

11

First Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China, 710061

Actively Recruiting

12

the Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Actively Recruiting

13

Beijing You 'an Hospital, Capital Medical University

Beijing, China

Actively Recruiting

14

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Beijing, China

Actively Recruiting

15

Chinese PLA General Hospital

Beijing, China

Suspended

16

Chongqing Cancer Hospital

Chongqing, China

Actively Recruiting

17

Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, China

Actively Recruiting

Loading map...

Research Team

Y

Yue Han, Professor

CONTACT

H

Han

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation | DecenTrialz